Grown for Centuries, Patented in 1997

Increasing food production can, in principle, follow three genuinely different paths: agrochemical-based agriculture, organic agriculture, or genetically engineered crop-based agriculture. The Green Revolution, built mainly on improved crop varieties combined with better management practices and heavier agrochemical use, tripled food supply, yet even that was not enough to keep pace with a still-growing human population, and further gains through conventional breeding alone have genuinely levelled off, while agrochemicals themselves remain too expensive for many farmers in the developing world. Traditional breeding techniques simply could not keep pace with demand fast enough, which is exactly what drove development of an entirely different technology, tissue culture, discovered during the 1950s when scientists learned that whole plants could actually be regenerated from an explant, any small piece of a plant grown in vitro under sterile conditions in a specially formulated nutrient medium. This capacity, any single cell or explant carrying the full potential to regenerate a complete plant, is called totipotency, and it depends on a nutrient medium supplying a carbon source like sucrose alongside inorganic salts, vitamins, amino acids and plant growth regulators like auxins and cytokinins.

Applying tissue culture at scale lets thousands of genetically identical plants, called somaclones, be produced in a genuinely short time, a process called micropropagation, already used commercially for important food plants like tomato, banana and apple. A further, genuinely practical application recovers healthy plants from ones already infected with a virus: even in an infected plant, the meristem itself, both apical and axillary, stays virus-free, so removing and growing just the meristem in vitro yields entirely virus-free plants, a technique already succeeding with banana, sugarcane and potato. Scientists have gone further still, isolating single plant cells and digesting away their cell walls entirely to obtain naked protoplasts, cells surrounded only by their plasma membrane; protoplasts from two different plant varieties, each carrying its own desirable trait, can then be fused together to form a hybrid protoplast, grown further into an entirely new plant, called a somatic hybrid, the whole process called somatic hybridisation. A tomato protoplast fused with a potato protoplast this way genuinely produced a hybrid plant nicknamed the pomato, combining traits from both parent plants, though it unfortunately never combined enough of the actually desirable traits to become commercially useful.

Plants, bacteria, fungi and animals whose own genes have been deliberately altered by direct manipulation are called genetically modified organisms, or GMOs, and genetically modified plants specifically have delivered several genuine benefits: greater tolerance to abiotic stresses like cold, drought, salinity and heat; reduced reliance on chemical pesticides through built-in pest resistance; reduced post-harvest losses; more efficient mineral usage, which helps prevent premature soil fertility exhaustion; and enhanced nutritional value, golden rice, genetically enriched with vitamin A, being a well-known example. GM technology has also been used to create genuinely tailor-made plants supplying alternative industrial resources, starches, fuels and pharmaceuticals among them, well beyond food production alone.

Certain Bacillus thuringiensis strains produce proteins genuinely toxic to specific insect groups, lepidopterans like tobacco budworm and armyworm, coleopterans like beetles, and dipterans like flies and mosquitoes, forming protein crystals during a particular growth phase. The bacterium itself survives its own toxin because the toxin exists inside these crystals purely as an inactive protoxin, only converting into its active, toxic form once an insect actually ingests it and the insect gut's own alkaline pH dissolves the crystal; the resulting activated toxin binds directly to midgut epithelial cell surfaces, creating pores that cause the cells to swell and rupture, eventually killing the insect. Specific Bt toxin genes, most insect-group specific, have been isolated and incorporated directly into crop plants like cotton, the toxin coded by genes collectively named cry, cryIAc and cryIIAb specifically controlling cotton bollworms and cryIAb controlling corn borer, letting crops manufacture their own targeted insecticide internally rather than needing external chemical spraying at all.

The nematode Meloidogyne incognitia infects tobacco plant roots, causing genuinely serious yield loss, and one specifically clever strategy for preventing this infestation relies on RNA interference, or RNAi, a natural cellular defence mechanism present in all eukaryotic organisms, working by silencing a specific messenger RNA through binding of a complementary double-stranded RNA molecule that physically blocks that mRNA's translation. Using Agrobacterium vectors, scientists introduced nematode-specific genes into host tobacco plants in a genuinely deliberate way, engineered to produce both sense and antisense RNA simultaneously inside the plant's own cells; because these two RNA strands are complementary to each other, they naturally form double-stranded RNA, triggering the plant's own RNAi machinery and silencing the nematode's specific mRNA directly. The consequence is genuinely elegant: the nematode parasite simply cannot survive inside a transgenic host actively expressing this interfering RNA, and the transgenic plant ends up protecting itself from infestation using a defence mechanism the nematode's own biology never anticipated.

Recombinant DNA technology has transformed healthcare directly by enabling mass production of safer, more effective therapeutic drugs, roughly 30 recombinant therapeutics now approved worldwide, 12 already marketed in India, and, because these products are structurally identical to their natural human counterparts, they avoid the unwanted immune reactions that similar products isolated from non-human sources often provoked. Insulin, needed at regular intervals to manage adult-onset diabetes, was historically extracted from slaughtered cattle and pig pancreas, a source that genuinely triggered allergic or other adverse reactions in some patients simply because the protein, though similar, was not truly human. Human insulin itself consists of two short polypeptide chains, A and B, linked by disulfide bridges, and is naturally synthesised as a pro-hormone carrying an extra C-peptide segment removed only during final maturation; the genuine engineering challenge in producing it recombinantly was assembling these separate chains into their correctly folded, mature form. In 1983, the American company Eli Lilly solved this by preparing separate DNA sequences for the A and B chains, introducing each into its own E. coli plasmid, producing the two chains independently, then extracting and chemically joining them through disulfide bond formation to create fully functional human insulin. Gene therapy takes recombinant technology a genuine step further, attempting to correct a diagnosed genetic defect directly by inserting a normal gene into a patient's own cells or tissues to compensate for a non-functional one; the first clinical gene therapy, given in 1990 to a four-year-old girl with adenosine deaminase, or ADA, deficiency, a disorder crippling immune function, worked by growing the patient's own blood lymphocytes in culture outside the body, introducing a functional ADA gene using a retroviral vector, and returning the modified lymphocytes to the patient, though since these cells are not immortal, this specific approach requires periodic repeat treatment rather than offering a single, permanent cure; correcting the same gene at the embryonic stage instead would, in principle, provide exactly that permanent fix. Molecular diagnosis techniques let disease be detected considerably earlier than conventional serum or urine analysis ever could: PCR amplifies even extremely low concentrations of a pathogen's own nucleic acid, letting infections like HIV or cancer-causing mutations be detected well before visible symptoms actually appear, while a radioactively tagged, single-stranded DNA or RNA probe can be hybridised against a cell clone's DNA to specifically identify mutated genes through autoradiography, and ELISA detects infection through direct antigen-antibody interaction, identifying either the pathogen's own antigens or the antibodies a patient's body has produced against it.

Transgenic animals, animals whose DNA has been deliberately manipulated to carry and express an extra foreign gene, have been created across rats, rabbits, pigs, sheep, cows and fish, though mice alone make up over 95 percent of all existing transgenic animals, created for several genuinely distinct reasons. Studying normal physiology and development, transgenic animals let researchers observe how specific genes are regulated and how they actually affect body function and development directly, insulin-like growth factor's biological role, for instance, studied by introducing genes from other species that alter how that factor forms and observing the resulting biological effects. Studying disease, transgenic animals engineered as models for human diseases like cancer, cystic fibrosis, rheumatoid arthritis and Alzheimer's let entirely new treatments be investigated safely before ever reaching human trials. Producing biological products, transgenic animals carrying a gene coding for a specific desired human protein can manufacture that protein directly and comparatively cheaply; Rosie, the first transgenic cow, produced in 1997, generated milk enriched with human alpha-lactalbumin at 2.4 grams per litre, nutritionally more balanced for human infants than ordinary cow's milk, and similar strategies have targeted proteins for treating emphysema, phenylketonuria and cystic fibrosis. Testing vaccine safety, transgenic mice engineered to be genuinely useful models are already being used to test polio vaccine safety, potentially replacing monkeys for this specific purpose if the approach proves sufficiently reliable. And testing chemical safety, transgenic animals engineered to be more sensitive to specific toxic substances than ordinary animals let toxicity testing return genuinely faster, more reliable results.

Manipulating living organisms simply cannot continue indefinitely without real regulation, and genuine ethical standards are needed to evaluate the morality of human activity that might help or harm other living things, alongside the genuinely unpredictable biological consequences that can follow when a genetically modified organism is introduced into a real ecosystem. India specifically set up the Genetic Engineering Approval Committee, or GEAC, to formally decide on GM research's validity and the actual safety of releasing GM organisms for public use. A separate but genuinely related problem has emerged around patents covering living organisms and biological resources used for public services: growing public frustration exists over companies obtaining patents on products and technologies built from genetic material, plants and other biological resources that farmers and indigenous communities in specific regions had already identified, developed and used for generations. India's own rice diversity runs genuinely deep, an estimated 200,000 varieties nationwide, Basmati rice specifically distinctive for its aroma and flavour, with 27 documented varieties grown across the country and centuries of reference in traditional texts, folklore and poetry; in 1997, an American company nonetheless obtained US patent rights covering Basmati rice, letting it market a supposedly 'new' variety, in reality derived directly from existing Indian farmers' varieties crossed with semi-dwarf types and then claimed as a genuine invention, a patent whose reach extended even to functionally equivalent varieties, potentially restricting other legitimate Basmati sellers entirely. Similar attempts have targeted patents on products and processes based on India's own traditional herbal medicine, turmeric and neem among them. Biopiracy is the specific term for exactly this pattern, multinational companies and other organisations using bio-resources without proper authorisation from, or compensation to, the actual countries and communities involved, a pattern with a genuinely stark global asymmetry: industrialised nations tend to be financially wealthy but comparatively poor in biodiversity and traditional knowledge, while developing and underdeveloped nations tend to hold genuinely rich biodiversity and traditional knowledge that can be commercially exploited far more cheaply and quickly than starting from scratch. Growing recognition of this injustice, and of the genuinely inadequate compensation and benefit-sharing that has followed, has pushed several nations to actively develop legal protections against unauthorised exploitation, with the Indian Parliament specifically clearing a second amendment to the Indian Patents Bill addressing exactly these concerns, including patent terms, emergency provisions, and research and development considerations.